Tianjin Chase Sun Pharmaceutical Co Ltd (300026) - Net Assets
Based on the latest financial reports, Tianjin Chase Sun Pharmaceutical Co Ltd (300026) has net assets worth CN¥8.72 Billion CNY (≈ $1.28 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥10.37 Billion ≈ $1.52 Billion USD) and total liabilities (CN¥1.65 Billion ≈ $241.01 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 300026 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥8.72 Billion |
| % of Total Assets | 84.11% |
| Annual Growth Rate | 39.75% |
| 5-Year Change | 19.03% |
| 10-Year Change | 66.33% |
| Growth Volatility | 147.4 |
Tianjin Chase Sun Pharmaceutical Co Ltd - Net Assets Trend (2006–2024)
This chart illustrates how Tianjin Chase Sun Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Tianjin Chase Sun Pharmaceutical Co Ltd to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Tianjin Chase Sun Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual net assets of Tianjin Chase Sun Pharmaceutical Co Ltd from 2006 to 2024. For live valuation and market cap data, see 300026 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥8.80 Billion ≈ $1.29 Billion |
-0.78% |
| 2023-12-31 | CN¥8.87 Billion ≈ $1.30 Billion |
+4.78% |
| 2022-12-31 | CN¥8.46 Billion ≈ $1.24 Billion |
+6.42% |
| 2021-12-31 | CN¥7.95 Billion ≈ $1.16 Billion |
+7.58% |
| 2020-12-31 | CN¥7.39 Billion ≈ $1.08 Billion |
+4.55% |
| 2019-12-31 | CN¥7.07 Billion ≈ $1.03 Billion |
+7.52% |
| 2018-12-31 | CN¥6.58 Billion ≈ $962.28 Million |
+1.04% |
| 2017-12-31 | CN¥6.51 Billion ≈ $952.41 Million |
+7.78% |
| 2016-12-31 | CN¥6.04 Billion ≈ $883.64 Million |
+14.15% |
| 2015-12-31 | CN¥5.29 Billion ≈ $774.07 Million |
+124.28% |
| 2014-12-31 | CN¥2.36 Billion ≈ $345.13 Million |
+38.53% |
| 2013-12-31 | CN¥1.70 Billion ≈ $249.14 Million |
+22.79% |
| 2012-12-31 | CN¥1.39 Billion ≈ $202.91 Million |
+32.06% |
| 2011-12-31 | CN¥1.05 Billion ≈ $153.65 Million |
-4.34% |
| 2010-12-31 | CN¥1.10 Billion ≈ $160.63 Million |
+18.43% |
| 2009-12-31 | CN¥926.88 Million ≈ $135.63 Million |
+638.48% |
| 2008-12-31 | CN¥125.51 Million ≈ $18.37 Million |
+104.94% |
| 2007-12-31 | CN¥61.24 Million ≈ $8.96 Million |
+187.86% |
| 2006-12-31 | CN¥21.28 Million ≈ $3.11 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Tianjin Chase Sun Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 475877005752.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥4.74 Billion | 54.88% |
| Common Stock | CN¥3.00 Billion | 34.75% |
| Other Comprehensive Income | CN¥306.43 Million | 3.55% |
| Other Components | CN¥589.66 Million | 6.82% |
| Total Equity | CN¥8.64 Billion | 100.00% |
Tianjin Chase Sun Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Tianjin Chase Sun Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shandong Yisheng Livestock & Poultry Breeding Co Ltd
SHE:002458
|
$1.33 Billion |
|
Planisware SAS
PA:PLNW
|
$1.33 Billion |
|
HannStar Board Corp
TW:5469
|
$1.33 Billion |
|
Jingsu Jingshen Salt&Chem
SHG:603299
|
$1.33 Billion |
|
Polestar Automotive Holding UK PLC Class A ADS
NASDAQ:PSNY
|
$1.33 Billion |
|
M Yochananof and Sons Ltd
TA:YHNF
|
$1.33 Billion |
|
Vitrolife AB
ST:VITR
|
$1.33 Billion |
|
Zhiyang Innovation Technology Co. Ltd. A
SHG:688191
|
$1.33 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tianjin Chase Sun Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 8,710,063,623 to 8,643,891,935, a change of -66,171,688 (-0.8%).
- Net income of 21,467,329 contributed positively to equity growth.
- Dividend payments of 137,111,517 reduced retained earnings.
- Other comprehensive income increased equity by 18,967,119.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥21.47 Million | +0.25% |
| Dividends Paid | CN¥137.11 Million | -1.59% |
| Other Comprehensive Income | CN¥18.97 Million | +0.22% |
| Other Changes | CN¥30.51 Million | +0.35% |
| Total Change | CN¥- | -0.76% |
Book Value vs Market Value Analysis
This analysis compares Tianjin Chase Sun Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.75x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 238.08x to 0.75x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥0.01 | CN¥3.02 | x |
| 2007-12-31 | CN¥0.04 | CN¥3.02 | x |
| 2008-12-31 | CN¥0.08 | CN¥3.02 | x |
| 2009-12-31 | CN¥0.51 | CN¥3.02 | x |
| 2010-12-31 | CN¥0.44 | CN¥3.02 | x |
| 2011-12-31 | CN¥0.42 | CN¥3.02 | x |
| 2012-12-31 | CN¥0.58 | CN¥3.02 | x |
| 2013-12-31 | CN¥0.68 | CN¥3.02 | x |
| 2014-12-31 | CN¥0.91 | CN¥3.02 | x |
| 2015-12-31 | CN¥1.97 | CN¥3.02 | x |
| 2016-12-31 | CN¥1.98 | CN¥3.02 | x |
| 2017-12-31 | CN¥2.11 | CN¥3.02 | x |
| 2018-12-31 | CN¥2.13 | CN¥3.02 | x |
| 2019-12-31 | CN¥2.36 | CN¥3.02 | x |
| 2020-12-31 | CN¥2.38 | CN¥3.02 | x |
| 2021-12-31 | CN¥2.60 | CN¥3.02 | x |
| 2022-12-31 | CN¥2.79 | CN¥3.02 | x |
| 2023-12-31 | CN¥2.92 | CN¥3.02 | x |
| 2024-12-31 | CN¥4.03 | CN¥3.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tianjin Chase Sun Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.37%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 1.29x
- Recent ROE (0.25%) is below the historical average (16.13%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 34.60% | 13.09% | 0.53x | 4.96x | CN¥5.23 Million |
| 2007 | 65.20% | 33.58% | 0.68x | 2.86x | CN¥33.74 Million |
| 2008 | 51.30% | 34.43% | 0.86x | 1.73x | CN¥51.83 Million |
| 2009 | 8.74% | 35.97% | 0.21x | 1.15x | CN¥-11.72 Million |
| 2010 | 10.11% | 26.58% | 0.30x | 1.27x | CN¥1.14 Million |
| 2011 | 12.62% | 21.75% | 0.40x | 1.45x | CN¥25.39 Million |
| 2012 | 16.79% | 18.80% | 0.68x | 1.31x | CN¥93.50 Million |
| 2013 | 20.08% | 16.19% | 0.95x | 1.31x | CN¥170.47 Million |
| 2014 | 19.06% | 15.61% | 0.94x | 1.30x | CN¥212.43 Million |
| 2015 | 10.15% | 15.98% | 0.52x | 1.23x | CN¥7.98 Million |
| 2016 | 11.11% | 17.03% | 0.53x | 1.23x | CN¥65.58 Million |
| 2017 | 7.10% | 13.36% | 0.45x | 1.17x | CN¥-184.42 Million |
| 2018 | 3.29% | 4.99% | 0.56x | 1.17x | CN¥-429.72 Million |
| 2019 | 5.93% | 8.05% | 0.59x | 1.24x | CN¥-276.11 Million |
| 2020 | 7.97% | 8.84% | 0.64x | 1.41x | CN¥-146.02 Million |
| 2021 | 8.84% | 8.96% | 0.66x | 1.49x | CN¥-89.97 Million |
| 2022 | 7.53% | 9.39% | 0.53x | 1.52x | CN¥-204.79 Million |
| 2023 | 5.82% | 8.29% | 0.52x | 1.36x | CN¥-364.37 Million |
| 2024 | 0.25% | 0.37% | 0.52x | 1.29x | CN¥-842.92 Million |
Industry Comparison
This section compares Tianjin Chase Sun Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,632,988,841
- Average return on equity (ROE) among peers: 4.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tianjin Chase Sun Pharmaceutical Co Ltd (300026) | CN¥8.72 Billion | 34.60% | 0.19x | $1.33 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $565.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $654.09 Million | 2.17% | 0.78x | $359.03 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $0.00 | 0.00% | 0.00x | $4.30 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $973.90 Million | 0.17% | 0.60x | $2.52 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.41 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $3.19 Billion | 14.61% | 0.55x | $12.64 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $715.72 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $307.22 Million | 6.68% | 0.79x | $319.94 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.55 Billion | 4.67% | 3.16x | $916.75 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $25.04 Billion | 7.11% | 0.16x | $3.00 Billion |
About Tianjin Chase Sun Pharmaceutical Co Ltd
Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research and development, production, and sale of various pharmaceutical products in China and internationally. The company provides Chinese medicine formula granules, finished drugs, raw materials, medical devices and excipients, medical and health services, as well as smart supply chain for pharmaceuticals and medical devices. It serves th… Read more